Partnering
Partnering in action
Supporting the acceleration of cancer research, Abcam has partnered with Cancer Research UK for the development and commercialization of novel custom antibodies.
Cancer Research UK
Custom antibody partnership to accelerate cancer research
Helping save millions of lives, Cancer Research-UK (CRUK) is a charity that financially supports researchers in their pioneering work into the prevention, diagnosis and treatment of cancer.
Co-creating antibodies, enabling critical oncology applications
As CRUK-funded researchers work to unravel some of the important targets and pathways involved in driving cancer they often reach a blockade as there are no commercial antibodies available that target the specific key protein that they need to study, Alternatively, those antibodies that are available do not perform in a required research application.
Recognising Abcam’s outstanding track record in discovering, developing and manufacturing quality antibodies for reproducible results they have teamed up with the Company to develop antibodies against critical oncology targets for their research/experiments with potential future applications in diagnostics and treatments.
Global cancer researchers benefiting from Abcam’s wide geographical reach
Under the terms of the partnership, Abcam will develop custom antibodies and other protein-based binding reagents to targets identified by CRUK-funded researchers. In addition, Abcam’s global supply capability and co-location in major technology hubs throughout the world will enable these innovative reagents to be made readily accessible to the wider research and diagnostic community
The antibodies resulting from this partnership will expand scientists’ access to biological reagents, supporting research to further the understanding of cancer biology, help generate new diagnostic tools, and potentially be the basis for novel therapies.
“We are excited to be partnering with Abcam to expand our access to biological reagents and to create the tools our scientists need to help accelerate our understanding of cancer. Abcam’s antibody development capabilities and “end-to-end” expertise will help provide our researchers with antibody reagents that can be applied from early-stage R&D right through to the clinic.”
Tony Hickson
CBO at Cancer Research UK
Cancer Research UK
Custom antibody partnership to accelerate cancer research
Helping save millions of lives, Cancer Research-UK (CRUK) is a charity that financially supports researchers in their pioneering work into the prevention, diagnosis and treatment of cancer.
Co-creating antibodies, enabling critical oncology applications
As CRUK-funded researchers work to unravel some of the important targets and pathways involved in driving cancer they often reach a blockade as there are no commercial antibodies available that target the specific key protein that they need to study, Alternatively, those antibodies that are available do not perform in a required research application.
Recognising Abcam’s outstanding track record in discovering, developing and manufacturing quality antibodies for reproducible results they have teamed up with the Company to develop antibodies against critical oncology targets for their research/experiments with potential future applications in diagnostics and treatments.
Global cancer researchers benefiting from Abcam’s wide geographical reach
Under the terms of the partnership, Abcam will develop custom antibodies and other protein-based binding reagents to targets identified by CRUK-funded researchers. In addition, Abcam’s global supply capability and co-location in major technology hubs throughout the world will enable these innovative reagents to be made readily accessible to the wider research and diagnostic community
The antibodies resulting from this partnership will expand scientists’ access to biological reagents, supporting research to further the understanding of cancer biology, help generate new diagnostic tools, and potentially be the basis for novel therapies.
“We are excited to be partnering with Abcam to expand our access to biological reagents and to create the tools our scientists need to help accelerate our understanding of cancer. Abcam’s antibody development capabilities and “end-to-end” expertise will help provide our researchers with antibody reagents that can be applied from early-stage R&D right through to the clinic.”
Tony Hickson
CBO at Cancer Research UK
Enabling next breakthroughs for the global cancer research community
By working with Abcam, CRUK-researchers and the wider global cancer research community will be able to get the antibodies they need, faster, to do their ground-breaking research and discover their next breakthroughs.
Our partnership is supporting the urgent need worldwide for new cancer targets, diagnostics and therapeutics.
Estimated global cancer stats in 2040 (International Agency for Research on Cancer)
27.5 million
new cancer cases
16.3 million
cancer deaths
Discovery Drive, Cambridge
Biomedical Campus,
Cambridge, CB2 0AX, UK
+44 (0) 1223 696 000
VIEW PRODUCTS
abcam.comabcam.co.jp
abcam.cn
Statements
© Abcam plc. all rights reserved.
Abcam plc is incorporated in England and Wales, its main country of operation in the UK. Use of this website is subject to our Terms and Conditions of use and our Privacy Policy. Share price and news information on this site is updated dynamically from external data feeds. Static content was last updated on 09 Nov 2020.
Website by FisherPaul